ArticleJournal of asthma and allergy2026
Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Biologic therapies have improved clinical outcomes and quality of life in patients with asthma, and treatment adherence is important for their effectiveness. This study evaluated 12-month adherence patterns for five asthma biologics approved in Japan and their impact on clinical and economic outcomes in patients with severe asthma. Methods: This non-interventional, cross-sectional, retrospective cohort study used Japan's Medical Data Vision database (June 2009-September 2024). Adults with severe asthma, ≥30 days of continuous enrollment pre-biologic initiation and ≥12 months of follow-up were included. Adherence was assessed using medication possession ratio (MPR). Group-based trajectory modeling (GBTM) characterized distinct adherence trajectories over time, providing insights into heterogeneous adherence behaviors and subgroup patterns. Impact of biologic adherence on exacerbations (defined by hospital admissions, emergency department visits or requiring oral/intravenous corticosteroids), healthcare resource utilization (HCRU) and pharmacy costs were analyzed descriptively. Results: Among 2904 eligible patients, average MPR was 62.6%-72.6% across the five biologics. Over 90% of patients received ≥1 follow-up dose of their biologic; with average MPR increased by 1%-6% among these patients versus the overall cohort. The GBTM analysis was conducted in 2531 patients without a biologic switch during follow-up, identifying seven distinct clusters with MPR ranging from 10.0% to 94.8%. Patients were also classified as adherent (41.1%), partially adherent (28.1%), minimally adherent (3.2%), or treatment discontinuation (27.6%), based on dosing frequency and intervals. Mean exacerbation rates defined by hospital admissions were low (0.02-0.08 events per patient/year). Exacerbations of any type typically increased with declining biologic adherence. Decreased adherence was generally associated with increased HCRU and higher asthma-related pharmacy costs, particularly when biologic costs were excluded. Conclusion: Biologic adherence was consistently associated with fewer exacerbations, reduced HCRU and lower asthma-related pharmacy costs (excluding biologic costs), reinforcing the importance of optimizing adherence in patients with asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.